Doyle Anthony's most recent trade in Biocryst Pharmaceuticals Inc. was a trade of 250,100 Emp. Stock Option (Right to Buy) done . Disclosure was reported to the exchange on Dec. 19, 2024.
| Stock | Client Name | Client Category | Action | Reported to Exchange | Quantity | Post Transaction Holding | Traded % | Avg. Price | Value | Security Type |
|---|---|---|---|---|---|---|---|---|---|---|
| Biocryst Pharmaceuticals Inc. | Doyle Anthony | Chief Financial Officer | 19 Dec 2024 | 250,100 | 250,100 | - | - | Emp. Stock Option (Right to Buy) | ||
| Biocryst Pharmaceuticals Inc. | Anthony Doyle | Chief Financial Officer | 19 Dec 2024 | 120,700 | 380,328 (0%) | 0% | 0 | Common Stock | ||
| Biocryst Pharmaceuticals Inc. | Anthony Doyle | Chief Financial Officer | 19 Dec 2024 | 2,461 | 377,867 (0%) | 0% | 7.4 | 18,187 | Common Stock | |
| Biocryst Pharmaceuticals Inc. | Anthony Doyle | Chief Financial Officer | 14 Dec 2024 | 7,890 | 259,628 (0%) | 0% | 7.5 | 59,412 | Common Stock | |
| Biocryst Pharmaceuticals Inc. | Anthony Doyle | Chief Financial Officer | 14 May 2024 | 36,300 | 266,744 (0%) | 0% | 5.6 | 202,191 | Common Stock | |
| Biocryst Pharmaceuticals Inc. | Doyle Anthony | Chief Financial Officer | 19 Dec 2023 | 2,482 | 227,444 (0%) | 0% | 6.0 | 15,016 | Common Stock | |
| Biocryst Pharmaceuticals Inc. | Anthony Doyle | Chief Financial Officer | 14 Dec 2023 | 158,500 | 158,500 | - | - | Emp. Stock Option (Right to Buy) | ||
| Biocryst Pharmaceuticals Inc. | Doyle Anthony | Chief Financial Officer | 14 Dec 2023 | 34,000 | 235,401 (0%) | 0% | 0 | Common Stock | ||
| Biocryst Pharmaceuticals Inc. | Anthony Doyle | Chief Financial Officer | 14 Dec 2023 | 5,475 | 229,926 (0%) | 0% | 6.4 | 35,204 | Common Stock | |
| Biocryst Pharmaceuticals Inc. | Anthony Doyle | Chief Financial Officer | 19 Dec 2022 | 158,500 | 158,500 | - | - | Emp. Stock Option (Right to Buy) | ||
| Biocryst Pharmaceuticals Inc. | Anthony Doyle | Chief Financial Officer | 19 Dec 2022 | 34,000 | 197,966 (0%) | 0% | 0 | Common Stock | ||
| Biocryst Pharmaceuticals Inc. | Anthony Doyle | Chief Financial Officer | 15 Dec 2022 | 5,700 | 163,966 (0%) | 0% | 10.9 | 62,130 | Common Stock | |
| Biocryst Pharmaceuticals Inc. | Anthony Doyle | Chief Financial Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 14 Dec 2021 | 164,000 | 164,000 | - | - | Emp. Stock Option (Right to Buy) | |
| Biocryst Pharmaceuticals Inc. | Anthony Doyle | Chief Financial Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 14 Dec 2021 | 115,000 | 208,719 (0%) | 0% | 0 | Common Stock | |
| Biocryst Pharmaceuticals Inc. | Anthony Doyle | Chief Financial Officer | 23 Nov 2021 | 35,258 | 93,719 (0%) | 0% | 12.5 | 440,020 | Common Stock | |
| Biocryst Pharmaceuticals Inc. | Anthony Doyle | Chief Financial Officer | 15 Dec 2020 | 332,500 | 332,500 | - | - | Emp. Stock Option (Right to Buy) | ||
| Biocryst Pharmaceuticals Inc. | Anthony Doyle | Chief Financial Officer | 11 Aug 2020 | 54,000 | 54,000 (0%) | 0% | 4.1 | 220,320 | Common Stock |